FIELD: medicine.
SUBSTANCE: present group of inventions relates to medicine, namely to therapy, and concerns treating or preventing thrombosis or embolism. For that effective amount of compound 
formula IIA, or its pharmaceutically acceptable salt is introduced, where R is hydrogen or acetyl.
EFFECT: introduction of these compounds provides fast and effective correction of hemostasis with no disadvantages and side effects observed, when introducing other antithrombotic preparations, particularly clopidogrel.
17 cl, 8 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITHROMBOTIC COMPOUND | 2012 |
|
RU2604733C2 |
| THIENOPYRIDINE ESTER DERIVATIVE, CONTAINING CYANOGROUP, METHOD OF ITS OBTAINING, ITS APPLICATION AND BASED ON IT COMPOSITION | 2011 |
|
RU2526624C2 |
| COMPOSITION OF CLOPIDOGREL AND SULPHOALKYLESTER CYCLODEXTRIN (VERSIONS) AND METHODS OF TREATING DISEASES BY SAID COMPOSITION (VERSIONS) | 2008 |
|
RU2470636C2 |
| THROMBOSIS INHIBITOR PREPARATIONS | 2010 |
|
RU2538616C2 |
| DEUTERATED THIENOPIPERIDINE DERIVATIVES, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2716141C2 |
| PREPARATION BASED ON MIXTURE OF FLAVONOIDS WITH FREE B-CYCLE AND FLAVANES, AS THERAPEUTIC AGENT | 2006 |
|
RU2411941C2 |
| METHOD FOR TREATMENT OF THROMBOTHIC DISTURBANCES USING QUERCETIN-CONTAINING COMPOSITIONS | 2012 |
|
RU2642983C2 |
| PHARMACEUTICAL COMBINATIONS | 2000 |
|
RU2242232C2 |
| APPLICATION OF VALSARTAN OR METABOLITE THEREOF FOR INHIBITION OF THROMBOCYTE AGGREGATION | 2003 |
|
RU2334512C2 |
| PHARMACEUTICAL COMBINATION POSSESSING ANTIAGGREGANT AND LIPID-REGULATING ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2461379C2 |
